Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 24 studies | 46% ± 22% | |
astrocyte | 22 studies | 63% ± 20% | |
fibroblast | 20 studies | 26% ± 9% | |
pericyte | 19 studies | 31% ± 20% | |
ciliated cell | 18 studies | 71% ± 21% | |
epithelial cell | 16 studies | 52% ± 25% | |
oligodendrocyte | 15 studies | 35% ± 14% | |
basal cell | 14 studies | 31% ± 10% | |
oligodendrocyte precursor cell | 12 studies | 36% ± 14% | |
myofibroblast cell | 12 studies | 40% ± 20% | |
glutamatergic neuron | 11 studies | 54% ± 17% | |
endothelial cell | 11 studies | 31% ± 13% | |
type I pneumocyte | 10 studies | 50% ± 19% | |
non-classical monocyte | 10 studies | 26% ± 11% | |
microglial cell | 10 studies | 41% ± 25% | |
neuron | 9 studies | 58% ± 20% | |
retinal cone cell | 9 studies | 84% ± 19% | |
retinal rod cell | 9 studies | 78% ± 22% | |
type II pneumocyte | 8 studies | 36% ± 19% | |
kidney loop of Henle epithelial cell | 8 studies | 58% ± 30% | |
goblet cell | 8 studies | 38% ± 13% | |
GABAergic neuron | 8 studies | 47% ± 16% | |
amacrine cell | 8 studies | 73% ± 23% | |
retinal ganglion cell | 8 studies | 81% ± 23% | |
connective tissue cell | 7 studies | 31% ± 10% | |
abnormal cell | 7 studies | 42% ± 20% | |
retina horizontal cell | 7 studies | 87% ± 23% | |
secretory cell | 7 studies | 35% ± 13% | |
ionocyte | 6 studies | 33% ± 8% | |
renal alpha-intercalated cell | 6 studies | 80% ± 28% | |
Mueller cell | 6 studies | 73% ± 23% | |
kidney distal convoluted tubule epithelial cell | 5 studies | 58% ± 13% | |
enterocyte | 5 studies | 40% ± 16% | |
progenitor cell | 5 studies | 77% ± 13% | |
retinal bipolar neuron | 5 studies | 76% ± 23% | |
OFF-bipolar cell | 5 studies | 82% ± 23% | |
ON-bipolar cell | 5 studies | 84% ± 19% | |
interneuron | 5 studies | 49% ± 7% | |
deuterosomal cell | 4 studies | 47% ± 10% | |
epithelial cell of proximal tubule | 4 studies | 25% ± 8% | |
enteroendocrine cell | 4 studies | 48% ± 21% | |
intestinal crypt stem cell | 4 studies | 35% ± 12% | |
GABAergic amacrine cell | 4 studies | 69% ± 27% | |
glycinergic amacrine cell | 4 studies | 58% ± 26% | |
neuroendocrine cell | 4 studies | 83% ± 3% | |
retinal pigment epithelial cell | 4 studies | 49% ± 9% | |
adventitial cell | 4 studies | 24% ± 12% | |
transit amplifying cell | 4 studies | 40% ± 13% | |
luminal cell of prostate epithelium | 4 studies | 43% ± 5% | |
precursor cell | 3 studies | 55% ± 28% | |
squamous epithelial cell | 3 studies | 52% ± 18% | |
pancreatic A cell | 3 studies | 34% ± 10% | |
type B pancreatic cell | 3 studies | 38% ± 18% | |
glomerular endothelial cell | 3 studies | 25% ± 6% | |
podocyte | 3 studies | 54% ± 8% | |
mesothelial cell | 3 studies | 21% ± 5% | |
neural crest cell | 3 studies | 61% ± 20% | |
renal principal cell | 3 studies | 56% ± 7% | |
brush cell | 3 studies | 30% ± 18% | |
club cell | 3 studies | 19% ± 2% | |
rod bipolar cell | 3 studies | 89% ± 8% | |
muscle cell | 3 studies | 52% ± 19% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 37% ± 10% | |
keratinocyte | 3 studies | 32% ± 13% | |
melanocyte | 3 studies | 32% ± 11% | |
granule cell | 3 studies | 49% ± 23% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 68906.74 | 2637 / 2642 | 99% | 1468.33 | 698 / 705 |
prostate | 98% | 42361.56 | 240 / 245 | 99% | 1001.50 | 496 / 502 |
intestine | 86% | 55576.83 | 830 / 966 | 69% | 632.08 | 364 / 527 |
stomach | 99% | 42584.54 | 357 / 359 | 52% | 398.48 | 148 / 286 |
kidney | 89% | 16836.29 | 79 / 89 | 61% | 302.31 | 548 / 901 |
uterus | 84% | 18407.12 | 143 / 170 | 63% | 239.84 | 289 / 459 |
thymus | 75% | 9821.86 | 491 / 653 | 67% | 198.82 | 404 / 605 |
bladder | 90% | 34961.29 | 19 / 21 | 42% | 264.71 | 214 / 504 |
ovary | 39% | 4560.53 | 71 / 180 | 66% | 200.60 | 282 / 430 |
ureter | 0% | 0 | 0 / 0 | 100% | 272.64 | 1 / 1 |
adrenal gland | 34% | 3566.71 | 87 / 258 | 59% | 207.83 | 135 / 230 |
esophagus | 67% | 43851.25 | 974 / 1445 | 22% | 49.33 | 41 / 183 |
heart | 89% | 18841.14 | 762 / 861 | 0% | 0 | 0 / 0 |
lung | 44% | 4828.50 | 253 / 578 | 43% | 111.97 | 494 / 1155 |
blood vessel | 61% | 12563.04 | 812 / 1335 | 0% | 0 | 0 / 0 |
skin | 35% | 3712.23 | 638 / 1809 | 16% | 44.20 | 76 / 472 |
tonsil | 0% | 0 | 0 / 0 | 44% | 137.56 | 20 / 45 |
adipose | 44% | 5811.00 | 530 / 1204 | 0% | 0 | 0 / 0 |
breast | 23% | 2984.05 | 104 / 459 | 15% | 40.17 | 173 / 1118 |
eye | 0% | 0 | 0 / 0 | 34% | 87.99 | 27 / 80 |
pancreas | 1% | 72.61 | 2 / 328 | 29% | 72.70 | 51 / 178 |
liver | 0% | 0 | 0 / 226 | 20% | 57.49 | 81 / 406 |
muscle | 17% | 2207.95 | 136 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 7% | 22.73 | 2 / 29 |
spleen | 0% | 31.95 | 1 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0140651 | Biological process | futile creatine cycle |
GO_0046314 | Biological process | phosphocreatine biosynthetic process |
GO_0021762 | Biological process | substantia nigra development |
GO_0005615 | Cellular component | extracellular space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0004111 | Molecular function | creatine kinase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005515 | Molecular function | protein binding |
GO_0005524 | Molecular function | ATP binding |
Gene name | CKB |
Protein name | Creatine kinase B-type (EC 2.7.3.2) (Brain creatine kinase) (B-CK) (Creatine kinase B chain) (Creatine phosphokinase B-type) (CPK-B) Creatine kinase B-type (EC 2.7.3.2) (Creatine kinase B chain) Creatine kinase B |
Synonyms | CKBB hCG_25499 HEL-S-29 |
Description | FUNCTION: Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate) . Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa (Probable). Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle: localizes to the mitochondria of thermogenic fat cells and acts by mediating phosphorylation of creatine to initiate a futile cycle of creatine phosphorylation and dephosphorylation (By similarity). During the futile creatine cycle, creatine and N-phosphocreatine are in a futile cycle, which dissipates the high energy charge of N-phosphocreatine as heat without performing any mechanical or chemical work (By similarity). . |
Accessions | P12277 G3V4N7 ENST00000557530.1 H0YJG0 A0A0S2Z471 ENST00000555039.1 G3V2I1 ENST00000553652.5 V9HWH2 ENST00000554989.1 ENST00000348956.7 H0YJK0 ENST00000689346.1 ENST00000553878.5 H0YJJ7 ENST00000553610.5 G3V461 |